allbcis.com

Every brain–computer interface on earth

private-startup  ·  therapeutic  ·  neurostimulation

Flow Neuroscience

At a glance

Legal name
Aliases
Type
private-startup
Focus areas
therapeutic, neurostimulation, consumer-wellness, clinical-grade
Founded
Defunct
Spinout of
HQ city
Malmö
HQ country
SE
Employees
Flagship device
flow-neuroscience-headset
Product lines
1
In-house manufacturing
Open source
No
GitHub org
Website
flowneuroscience.com
Blog
Support
help.flowneuroscience.com

Devices

People

Founders

  1. TechRound — Daniel Mansson interview (founders, Malmö HQ)https://techround.co.uk/interviews/a-chat-with-daniel-mansson-founder-at-healthtech-company-flow-neuroscience/
Updated: 2026-05-04

  • Daniel Mansson

    Co-Founder, CEO

  • Erik Rehn

    Co-Founder

Current leadership

  1. TechRound — Daniel Mansson interview (founders, Malmö HQ)https://techround.co.uk/interviews/a-chat-with-daniel-mansson-founder-at-healthtech-company-flow-neuroscience/
  2. Medical Device Network — FDA approves Flow FL-100https://www.medicaldevice-network.com/news/fda-clears-flow-neuroscience-at-home-depression-treatment-in-us-first/2025-12-11
Updated: 2026-05-04

  • Daniel Mansson

    CEO

  • Kultar Garcha

    Chief Medical Officer

Milestones

  1. Flow Neuroscience founded in Malmö

  2. CE-MDR Class IIa clearance

    CE Class IIa medical-device clearance for adult major depressive disorder in Europe and the UK.

  3. Nature Medicine RCT publishes positive results

    Randomised sham-controlled trial showing remission and response benefits over 10 weeks of home tDCS use.

  4. FDA PMA approval (P230024) for the Flow FL-100

    First at-home tDCS device approved by the FDA for the treatment of major depressive disorder in adults; US launch planned Q2 2026.

Reputation

Widely regarded as the most clinically-credible consumer-form-factor brain-stim company. Daniel Mansson is a registered clinical psychologist and frequently presents Flow's RCT evidence at academic depression-treatment conferences. Distinct from the DIY / biohacker tDCS scene by virtue of the medical-device pathway and prescription-clinician model.

Sources